NCT04914546

A Study of LY3819469 in Healthy Participants

A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3819469

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a 2-part study. In Part A, the main purpose is to evaluate the safety and tolerability of the study drug LY3819469 in healthy participants with high lipoprotein (a) \[Lp(a)\] levels. How the body processes the study drug and the effect of the study drug on blood Lp(a) levels will also be investigated. Part B will mainly evaluate the safety and tolerability of LY3819469 as well as how the body processes the study drug in Japanese participants. The study may last up to 53 and 29 weeks for each participant in Parts A and B, respectively.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3819469	Administered SC.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2021-06-14
• Primary completion: 2022-11-09
• Completion: 2022-11-09
• First posted: 2021-06-04
• Last updated: 2022-11-21

Locations

5 sites across 2 countries: United States, Singapore

Regulatory

• FDA-regulated drug study